Skip to main content

SIGNIFICANTLY MORE PATIENTS HAD WELL‑CONTROLLED SYMPTOMS

CUPID-A

a P=0.0133; OR (95% CI): 3.09 (1.24, 7.69).

b P=0.0034; OR (95% CI): 3.23 (1.43, 7.27).

CUPID-C
≈1.8x

as many patients were urticaria-free (UAS7=0) at Week 24;
30% on DUPIXENT (n=73) vs 17% on placebo (n=75; P=0.0165; secondary endpoint)1,2,c

≈1.7x

as many patients had well-controlled symptoms (UAS7≤6) at Week 24;
40% on DUPIXENT (n=73) vs 23% on placebo (n=75; P=0.0062; secondary endpoint)1,2,d

cOR (95% CI): 2.73 (1.15, 6.50).

dOR (95% CI): 3.05 (1.32, 7.02).

UAS7, urticaria activity score over 7 days.